Supreme Court Declines CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court refused to hear CareDx's appeal in its false-advertising clash with diagnostics rival Natera, leaving a lower court ruling intact.
The U.S. Supreme Court has declined to take up an appeal filed by transplant diagnostics company CareDx in its ongoing legal battle with competitor Natera over false-advertising claims. By rejecting the petition, the justices allowed a lower court's decision to stand without comment, a common but consequential move that effectively closes CareDx's avenue for federal review at the nation's highest court.
The dispute centers on allegations related to advertising practices in the competitive molecular diagnostics space, where both companies market kidney transplant monitoring tests. False-advertising litigation of this kind typically hinges on whether marketing claims mislead physicians or patients in ways that cause measurable competitive harm — a legal standard that courts have applied with varying rigor across circuits.
Read more Wells Fargo Reaffirms Buy Rating on Affirm Holdings →
For Natera, the Supreme Court's refusal to intervene represents a significant litigation milestone, reinforcing whatever legal posture it had secured in the appellate proceedings below. For CareDx, the denial forecloses what had been its last realistic path to reversing an unfavorable ruling through federal courts, forcing the company to reckon with the legal and reputational implications of the outcome.
The case illustrates the intensifying competition in the transplant diagnostics market, where rival firms increasingly turn to the courts as a competitive tool alongside clinical differentiation. Investors in both companies will likely scrutinize how the final resolution affects commercial messaging strategies and any potential damages exposure that may remain unresolved at lower court levels.
Continue reading at Yahoo Finance.
